ClinicaliQ Trial Snapshot
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — Recruiting • Phase III • Oncology • NCT07252232.
- What is being tested: Daraxonrasib (RMC-6236), a novel RAS(ON) inhibitor, is being evaluated for safety and efficacy as adjuvant therapy in resected pancreatic ductal adenocarcinoma (PDAC), compared against standard observation alone.
- Patient eligibility overview: The trial enrolls patients with completely resected PDAC who are candidates for adjuvant treatment; specific eligibility criteria regarding tumour stage, performance status, and organ function would be detailed in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Eligibility Snapshot
- : * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease. * Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy. * Must have completed most recent treatment within the past 12 weeks. * Adequate organ function (bone marrow, liver, kidney, coagulation). * Documented RAS mutation status. * Able to take oral medications.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.